- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab 300 MG in 15 ML Injection
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 462
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Nusinersen, Sham procedure
- Drug · Procedure
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- alefacept, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 10
- States / cities
- Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- dimethyl fumarate, Interferon β-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
- Interventions
- Assessments
- Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • Boca Raton, Florida + 8 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Felzartamab, Tacrolimus, Standard of Care IST
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 16
- States / cities
- Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more
- Conditions
- Sickle Cell Disease
- Interventions
- Motixafortide, Natalizumab, Leukapheresis
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Interventions
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Methotrexate, IV methylprednisolone
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Major Depressive Disorder
- Interventions
- SAGE-217, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 46
- States / cities
- Bentonville, Arkansas • Bellflower, California • Garden Grove, California + 40 more
- Conditions
- Multiple Sclerosis, Exposure During Pregnancy
- Interventions
- Dimethyl fumarate, Peginterferon beta-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Female only
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Advanced Solid Tumors, Lymphoid Malignancies
- Interventions
- Bardoxolone methyl
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 192
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 170 more
- Conditions
- Crohn's Disease
- Interventions
- natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lupus Nephritis
- Interventions
- Felzartamab
- Drug
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- La Jolla, California • San Francisco, California • Stanford, California + 9 more
- Conditions
- Psoriasis
- Interventions
- Mechanism of action of alefacept
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Healthy Volunteers
- Interventions
- Avonex
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Parkinson Disease
- Interventions
- BIIB122 225 mg, BIIB122-Matching Placebo
- Drug · Other
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boca Raton, Florida + 4 more
- Conditions
- Euvolemic Hyponatremia
- Interventions
- Lixivaptan, Placebo
- Drug
- Lead sponsor
- CardioKine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more
- Conditions
- Healthy Volunteers
- Interventions
- Aducanumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Anaheim, California • South Miami, Florida
- Conditions
- Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT)
- Interventions
- 90Y Ibritumomab tiuxetan
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Rocky Mountain MS Research Group, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah